Investigating Alzheimer’s Disease Progression Using a Radiomics Approach: The Hippocampal-Amygdala Border in FDG-Positron Emission Tomography Scans
This study establishes the clinical potential of radiomics in providing highly sensitive and interpretable biomarkers for monitoring AD progression, specifically by targeting the novel, biologically informed hippocampal-amygdala border ROI on FDG-PET. By identifying distinct, parsimonious sets of robust radiomic features for different disease stages, our approach offers an efficient, noninvasive, and clinically translatable tool that balances diagnostic power with interpretability, paving the way for its integration into existing clinical workflows for AD.
Authors
- Ramin Rasi (ORCID: https://orcid.org/0009-0009-6657-2355)
- Albert Güveniş (ORCID: https://orcid.org/0000-0003-0490-5184)
- the Alzheimer’s Disease Neuroimaging Initiative
Institutions
- Biruni University (TR)
- Boğaziçi University (TR)
Publication Details
- Journal
- Neurodegenerative Diseases
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1159/000550231
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Boğaziçi Üniversitesi
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research